References
- Borghi A, Corazza M, Mantovani L, et al. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol. 2012;51:1512–16.
- Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170:274–303.
- Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438–53.
- Peluso AM, Bardazzi F, Tosti A, Varotti C. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Acta Derm Venereol Suppl (Stockh). 1994;186:90–1.
- Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366–75.
- Weinster GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 1993;28:454–9.
- Altomare G, Ayala F, Bardazzi F, et al. Italian consensus conference. Consensus on the use of cyclosporine in dermatological practice. Italian consensus conference. G Ital Dermatol Venereol. 2014;149:607–25.
- Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10:S1–95.
- O'Brien E, Asmar R, Beilin L, et al. European society of hypertension working group on blood pressure monitoring. J Hypertens. 2005;23:697–701.
- Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623–9.
- Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;26: 12–20.
- Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25:19–27.
- Chaidemenos GC, Mourellou O, Avgoustinaki N, et al. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007;21:1203–8.
- Lachapelle JM, Marot L, Jablonska S. Superficial granulomatous pyoderma gangrenosum of the face, successfully treated by ciclosporine: a long-term follow-up. Dermatology. 2001;202:155–7.
- Powles AV, Hardman CM, Porter WM, et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol. 1998;138:443–9.
- Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996;35:710–9.
- Griffiths CEM, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150:11–23.
- Wozniak DF, Hartman RE, Boyle MP, et al. Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis. 2004;17:403–14.
- Lamarche F, Carcenac C, Gonthier B, et al. Mitochondrial permeability transition pore inhibitors prevent ethanol-induced neuronal death in mice. Chem Res Toxicol. 2013;26:78–88.
- Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012;4:11–21.
- Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA. 2013;149:1173–9.
- Antonucci VA, Tengattini V, Balestri R, et al. Intima-media thickness in an Italian psoriatic population: correlation with lipidic serum levels, PASI and BMI. J Eur Acad Dermatol Venereol. 2014;28:512–15.
- Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology (Basel). 2008;216:366–72.
- Radtke MA, Reich K, Spehr C, Augustin M. Treatment goals in psoriasis routine care. Arch Dermatol Res. 2015;307:445–9.